phenobarbital has been researched along with Asphyxia Neonatorum in 38 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Asphyxia Neonatorum: Respiratory failure in the newborn. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen term asphyxiated newborns treated with mild whole body hypothermia, started within 6 h after birth and protracted for 72 h, received phenobarbital for clinical seizures." | 9.15 | Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ( Cavallaro, G; Donzelli, G; Favelli, F; Filippi, L; Fiorini, P; Guerrini, R; la Marca, G; Malvagia, S, 2011) |
| "The current study uses a population modeling approach to evaluate and quantify the impact of severity of asphyxia and hypoxic-ischemic encephalopathy (HIE) on the pharmacokinetics of phenobarbital in asphyxiated newborns treated with therapeutic hypothermia." | 8.12 | Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain inter-individual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia. ( Hronová, K; Krekels, EH; Michaličková, D; Pokorná, P; Slanař, O; Tibboel, D; Völler, S, 2022) |
| "Bumetanide was suggested as an adjunct to phenobarbital for suppression of neonatal seizures." | 8.02 | A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia. ( Gailus, B; Gericke, B; Johne, M; Käufer, C; Löscher, W; Römermann, K, 2021) |
| "Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia." | 5.62 | Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. ( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021) |
| "Nineteen term asphyxiated newborns treated with mild whole body hypothermia, started within 6 h after birth and protracted for 72 h, received phenobarbital for clinical seizures." | 5.15 | Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ( Cavallaro, G; Donzelli, G; Favelli, F; Filippi, L; Fiorini, P; Guerrini, R; la Marca, G; Malvagia, S, 2011) |
| "To determine whether 40 mg/kg phenobarbital given to term infants with severe asphyxia would result in a lower incidence of seizures in the newborn period and an improved neurologic outcome." | 5.08 | High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up. ( Daily, DK; Hall, FK; Hall, RT, 1998) |
| "A double blind randomized study has been performed in 17 newborn infants bearing a diagnosis of perinatal asphyxia and treated with phenobarbital (FB) or phenytoin (DPH) to prevent the onset of seizures." | 5.06 | [Preventive treatment of convulsions in perinatal asphyxia]. ( Chunga, F; Durán, JA; Serrano, JS; Valls, A; Vela, F, 1987) |
| "Ganaxolone provided better seizure control than phenobarbital in this perinatal asphyxia model and was neuroprotective for the newborn brain, affording a new therapeutic opportunity for treatment of neonatal seizures." | 4.12 | Ganaxolone versus Phenobarbital for Neonatal Seizure Management. ( Allison, BJ; Bennet, L; Boyd, BJ; Castillo-Melendez, M; Fahey, MC; Hirst, JJ; Hunt, RW; Jenkin, G; Malhotra, A; McDonald, C; Mihelakis, J; Miller, SL; Nitsos, I; Pham, Y; Sutherland, AE; Walker, DW; Wong, F; Yawno, T, 2022) |
| "The current study uses a population modeling approach to evaluate and quantify the impact of severity of asphyxia and hypoxic-ischemic encephalopathy (HIE) on the pharmacokinetics of phenobarbital in asphyxiated newborns treated with therapeutic hypothermia." | 4.12 | Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain inter-individual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia. ( Hronová, K; Krekels, EH; Michaličková, D; Pokorná, P; Slanař, O; Tibboel, D; Völler, S, 2022) |
| "Bumetanide was suggested as an adjunct to phenobarbital for suppression of neonatal seizures." | 4.02 | A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia. ( Gailus, B; Gericke, B; Johne, M; Käufer, C; Löscher, W; Römermann, K, 2021) |
| " Fluid restriction and treatment of seizures with phenobarbital are widely used therapies." | 3.67 | Neonatal hypoxic-ischemic encephalopathy: current management practices. ( Donn, SM; Goldstein, GW; Schork, MA, 1988) |
| "The conventional loading dose of phenobarbital for newborn infants with hypoxic-ischemic seizures, 20 mg/kg, often fails to control convulsive activity." | 3.67 | Safety of a higher loading dose of phenobarbital in the term newborn. ( Donn, SM; Goldstein, GW; Grasela, TH, 1985) |
| "Phenobarbital has the advantage of low cost and simplicity." | 2.78 | High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. ( Avasiloaiei, A; Dimitriu, C; Moscalu, M; Paduraru, L; Stamatin, M, 2013) |
| "Phenobarbital data were collected between 2008 and 2010." | 2.77 | Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. ( de Vries, LS; Egberts, AC; Groenendaal, F; Huitema, AD; Rademaker, CM; Toet, MC; van den Broek, MP; van Hasselt, JG; van Straaten, HL, 2012) |
| "Seizures are common following perinatal asphyxia and may exacerbate secondary neuronal injury." | 2.53 | Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia. ( Berg, M; Soll, R; Young, L, 2016) |
| "It is the recommended drug for the treatment of seizures in term neonates." | 2.37 | [Phenobarbital in newborn infants. Overview]. ( Staudt, F, 1984) |
| "Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia." | 1.62 | Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. ( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021) |
| "To assess pharmacokinetics and clinical anti-epileptic effectiveness of phenobarbital and midazolam in asphyxiated neonates and to develop dosing guidelines." | 1.51 | Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. ( Cools, F; de Haan, TR; Dijk, PH; Dijkman, KP; Egberts, TCG; Favié, LMA; Groenendaal, F; Huitema, ADR; Nuytemans, DHGM; Rademaker, CMA; Rijken, M; Simons, SHP; van Bel, F; van den Broek, MPH; van der Lee, JH; van Heijst, A; van Straaten, HLM; Zecic, A; Zonnenberg, IA, 2019) |
| "Phenobarbital was maintained for 3 weeks to 6 months (mean 11 weeks)." | 1.30 | Outcome of neonatal stroke in full-term infants without significant birth asphyxia. ( Camfield, PR; Jan, MM, 1998) |
| "These were presence of seizures, grading of encephalopathy and neurobehavioural assessment at discharge from the hospital." | 1.30 | Clinical predictors of outcome in hypoxic ischaemic encephalopathy in term neonates. ( Aggarwal, P; Barve, S; Bhave, S; Chaudhari, S; Pandit, A, 1998) |
| "phenobarbital dosing requirements and plasma clearance were examined for asphyxiated and nonasphyxiated neonates." | 1.27 | The influence of asphyxia on phenobarbital dosing requirements in neonates. ( Boer, HR; Erkan, NV; Gal, P; Toback, J, 1984) |
| "Phenobarbital (20 mg/kg) was given intravenously to asphyxiated full term neonates who were less than 48 hours old." | 1.26 | [Value of the intravenous route for the use of phenobarbital in asphyxiated full term newborn infants]. ( Amine, A; Bourin, M; Breteau, M; Gold, F; Granry, JC; Laugier, J, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (28.95) | 18.7374 |
| 1990's | 8 (21.05) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 10 (26.32) | 24.3611 |
| 2020's | 5 (13.16) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, SL | 1 |
| Bennet, L | 1 |
| Sutherland, AE | 1 |
| Pham, Y | 1 |
| McDonald, C | 1 |
| Castillo-Melendez, M | 1 |
| Allison, BJ | 1 |
| Mihelakis, J | 1 |
| Nitsos, I | 1 |
| Boyd, BJ | 1 |
| Hirst, JJ | 1 |
| Walker, DW | 1 |
| Hunt, RW | 1 |
| Jenkin, G | 1 |
| Wong, F | 1 |
| Malhotra, A | 1 |
| Fahey, MC | 1 |
| Yawno, T | 1 |
| Welzel, B | 1 |
| Johne, M | 3 |
| Löscher, W | 3 |
| Pokorná, P | 1 |
| Michaličková, D | 1 |
| Völler, S | 1 |
| Hronová, K | 1 |
| Tibboel, D | 1 |
| Slanař, O | 1 |
| Krekels, EH | 1 |
| Römermann, K | 2 |
| Hampel, P | 1 |
| Gailus, B | 2 |
| Theilmann, W | 1 |
| Ala-Kurikka, T | 1 |
| Kaila, K | 1 |
| Käufer, C | 1 |
| Gericke, B | 1 |
| Allegaert, K | 1 |
| Smits, A | 1 |
| van den Anker, JN | 1 |
| Favié, LMA | 1 |
| Groenendaal, F | 2 |
| van den Broek, MPH | 1 |
| Rademaker, CMA | 1 |
| de Haan, TR | 1 |
| van Straaten, HLM | 1 |
| Dijk, PH | 1 |
| van Heijst, A | 1 |
| Simons, SHP | 1 |
| Dijkman, KP | 1 |
| Rijken, M | 1 |
| Zonnenberg, IA | 1 |
| Cools, F | 1 |
| Zecic, A | 1 |
| van der Lee, JH | 1 |
| Nuytemans, DHGM | 1 |
| van Bel, F | 1 |
| Egberts, TCG | 1 |
| Huitema, ADR | 1 |
| Avasiloaiei, A | 1 |
| Dimitriu, C | 1 |
| Moscalu, M | 1 |
| Paduraru, L | 1 |
| Stamatin, M | 1 |
| Hakan, N | 1 |
| Aydin, M | 1 |
| Yilmaz, O | 1 |
| Zenciroglu, A | 1 |
| Okumus, N | 1 |
| Spiers, H | 1 |
| Twesigomwe, G | 1 |
| Cartledge, P | 1 |
| Young, L | 1 |
| Berg, M | 1 |
| Soll, R | 1 |
| Filippi, L | 2 |
| la Marca, G | 2 |
| Fiorini, P | 2 |
| Poggi, C | 1 |
| Cavallaro, G | 2 |
| Malvagia, S | 2 |
| Pellegrini-Giampietro, DE | 1 |
| Guerrini, R | 2 |
| Gathwala, G | 1 |
| Marwah, A | 1 |
| Gahlaut, V | 1 |
| Marwah, P | 1 |
| Favelli, F | 1 |
| Donzelli, G | 1 |
| Sarkar, S | 1 |
| Barks, JD | 1 |
| Bapuraj, JR | 1 |
| Bhagat, I | 1 |
| Dechert, RE | 1 |
| Schumacher, RE | 1 |
| Donn, SM | 4 |
| van den Broek, MP | 1 |
| Toet, MC | 1 |
| van Straaten, HL | 1 |
| van Hasselt, JG | 1 |
| Huitema, AD | 1 |
| de Vries, LS | 1 |
| Egberts, AC | 1 |
| Rademaker, CM | 1 |
| Sykes, RM | 1 |
| Agarwal, R | 1 |
| Jain, A | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Gouyon, JB | 1 |
| Giroud, M | 1 |
| Staudt, F | 1 |
| Bjerre, I | 1 |
| Hellström-Westas, L | 2 |
| Rosén, I | 2 |
| Svenningsen, N | 1 |
| Ando, Y | 1 |
| Takashima, S | 1 |
| Takeshita, K | 1 |
| Gal, P | 1 |
| Toback, J | 1 |
| Erkan, NV | 1 |
| Boer, HR | 1 |
| Svenningsen, NW | 2 |
| Blennow, G | 1 |
| Lindroth, M | 1 |
| Gäddlin, PO | 1 |
| Ahlström, H | 1 |
| Vannucci, RC | 1 |
| Perlman, JM | 1 |
| Hall, RT | 1 |
| Hall, FK | 1 |
| Daily, DK | 1 |
| Ajayi, OA | 1 |
| Oyaniyi, OT | 1 |
| Chike-Obi, UD | 1 |
| Jan, MM | 1 |
| Camfield, PR | 1 |
| Aggarwal, P | 1 |
| Chaudhari, S | 1 |
| Bhave, S | 1 |
| Pandit, A | 1 |
| Barve, S | 1 |
| McBride, MC | 1 |
| Laroia, N | 1 |
| Guillet, R | 1 |
| Gold, F | 1 |
| Bourin, M | 1 |
| Granry, JC | 1 |
| Amine, A | 1 |
| Breteau, M | 1 |
| Laugier, J | 1 |
| Veerman, M | 1 |
| Espejo, MG | 1 |
| Christopher, MA | 1 |
| Knight, M | 1 |
| Goldstein, GW | 2 |
| Schork, MA | 1 |
| Vela, F | 1 |
| Durán, JA | 1 |
| Chunga, F | 1 |
| Serrano, JS | 1 |
| Valls, A | 1 |
| Hill, A | 1 |
| Grasela, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: a Pilot Study of the Neonatal Neuroprotection of Asphyxiated Tuscan Infants (NeoNATI) Network[NCT01241019] | Phase 2 | 64 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Protecting Brains and Saving Futures - the PBSF Protocol: a Prospective Multicenter and Observational Study on the Use of Telemedicine for Neurocritical Care in High-risk Newborns in Brazil.[NCT03786497] | 2,268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Not yet recruiting | |||
| A Randomized Clinical Trial of Therapeutic Hypothermia During Transport for Hypoxic Ischemic Encephalopathy (HIE): Device-regulated Cooling Versus Standard Practice.[NCT01683383] | 101 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants in target temperature range (33-34 C) anytime during transport (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Participants (Number) |
|---|---|
| Control (Standard Cooling) | 24 |
| Device (Servo-regulated Cooling) | 41 |
Percentage of participants in target range (33°-34°C) one hour after cooling initiation by the transport team (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Percentage of participants (Number) |
|---|---|
| Control (Standard Cooling) | 8 |
| Device (Servo-regulated Cooling) | 28 |
The percentage of temperatures in the target range (33°-34°C) during transport after cooling initiation by the transport team. (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Percentage of temperatures (Median) |
|---|---|
| Control (Standard Cooling) | 0 |
| Device (Servo-regulated Cooling) | 73 |
Time to the target temperature range (33°-34°C) from initiation of cooling by the transport team (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Minutes (Mean) |
|---|---|
| Control (Standard Cooling) | 63 |
| Device (Servo-regulated Cooling) | 44 |
The incidence, intervention and outcome of cardiac arrhythmia, major bleeding, altered skin integrity, pulmonary hypertension, device-related events, death, and other serious adverse events from the time of initiation of transport cooling to the time of completion will be monitored. (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cardiac arrhythmia | Major bleeding (pulmonary hemorrhage) | Altered skin integrity | Pulmonary hypertension | Device-related events | Death | |
| Control (Standard Cooling) | 0 | 0 | 0 | 0 | 0 | 6 |
| Device (Servo-regulated Cooling) | 0 | 1 | 0 | 0 | 2 | 9 |
6 reviews available for phenobarbital and Asphyxia Neonatorum
| Article | Year |
|---|---|
Question 1: Phenobarbital for preventing mortality and morbidity in full-term newborns with perinatal asphyxia in a resource-poor setting.
Topics: Asphyxia Neonatorum; Humans; Hypnotics and Sedatives; Hypoxia-Ischemia, Brain; Infant, Newborn; Morb | 2015 |
Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia.
Topics: Anticonvulsants; Asphyxia Neonatorum; Barbiturates; Humans; Infant; Infant, Newborn; Infant, Prematu | 2016 |
[Indications for phenobarbital in neonatal pathology].
Topics: Asphyxia Neonatorum; Cerebral Hemorrhage; Humans; Infant, Newborn; Infant, Newborn, Diseases; Jaundi | 1983 |
[Phenobarbital in newborn infants. Overview].
Topics: Asphyxia Neonatorum; Brain Injuries; Cerebral Hemorrhage; Electroencephalography; Half-Life; Humans; | 1984 |
Interventions for perinatal hypoxic-ischemic encephalopathy.
Topics: Animals; Asphyxia Neonatorum; Brain Damage, Chronic; Brain Ischemia; Calcium Channel Blockers; Excit | 1997 |
Pharmacologic considerations in the management of the asphyxiated newborn.
Topics: Asphyxia Neonatorum; Barbiturates; Brain; Brain Edema; Brain Ischemia; Free Radicals; Humans; Hypoxi | 1985 |
7 trials available for phenobarbital and Asphyxia Neonatorum
| Article | Year |
|---|---|
High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns.
Topics: Asphyxia Neonatorum; Birth Weight; Dose-Response Relationship, Drug; Epoetin Alfa; Erythropoietin; F | 2013 |
Effect of high-dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial.
Topics: Asphyxia Neonatorum; Glutathione Peroxidase; Hospitals, Teaching; Humans; Hypoxia-Ischemia, Brain; I | 2011 |
Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia.
Topics: Anticonvulsants; Asphyxia Neonatorum; Body Temperature; Humans; Hypothermia, Induced; Hypoxia-Ischem | 2011 |
Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach.
Topics: Anticonvulsants; Asphyxia Neonatorum; Drug Administration Schedule; Electroencephalography; Fluoresc | 2012 |
High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up.
Topics: Anticonvulsants; Asphyxia Neonatorum; Follow-Up Studies; Humans; Infant, Newborn; Phenobarbital; Pro | 1998 |
Electrographic seizures in neonates correlate with poor neurodevelopmental outcome.
Topics: Anticonvulsants; Asphyxia Neonatorum; Demography; Developmental Disabilities; Electroencephalography | 2000 |
[Preventive treatment of convulsions in perinatal asphyxia].
Topics: Asphyxia Neonatorum; Double-Blind Method; Female; Humans; Infant, Newborn; Male; Phenobarbital; Phen | 1987 |
25 other studies available for phenobarbital and Asphyxia Neonatorum
| Article | Year |
|---|---|
Ganaxolone versus Phenobarbital for Neonatal Seizure Management.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Disease Models, Animal; Epilepsy; H | 2022 |
Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Topics: Animals; Anticonvulsants; Asphyxia; Asphyxia Neonatorum; Bumetanide; Epilepsy; Humans; Infant, Newbo | 2023 |
Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain inter-individual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia.
Topics: Adult; Asphyxia; Asphyxia Neonatorum; Humans; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Infant, | 2022 |
Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Bumetanide; Disease Models, Animal; | 2021 |
A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Benzylamines; Brain; Bumetanide; Do | 2021 |
Phenobarbital Increases Midazolam Clearance in Neonates Treated with Hypothermia: Do We Really Need to Know?
Topics: Anticonvulsants; Asphyxia Neonatorum; Drug Therapy, Combination; Humans; Hypothermia, Induced; Infan | 2019 |
Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia.
Topics: Anticonvulsants; Asphyxia Neonatorum; Drug Interactions; Drug Therapy, Combination; Female; Humans; | 2019 |
Is phenobarbital a neuroprotective agent in newborn infants with perinatal asphyxia?
Topics: Asphyxia Neonatorum; Erythropoietin; Female; Humans; Male; Phenobarbital | 2014 |
Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy.
Topics: Asphyxia Neonatorum; Combined Modality Therapy; Drug Therapy, Combination; Female; Fructose; Humans; | 2009 |
Does phenobarbital improve the effectiveness of therapeutic hypothermia in infants with hypoxic-ischemic encephalopathy?
Topics: Asphyxia Neonatorum; Brain; Combined Modality Therapy; Female; Humans; Hypothermia, Induced; Hypoxia | 2012 |
Epilepsy in children in Benin City, Nigeria.
Topics: Adolescent; Age Distribution; Anticonvulsants; Asphyxia Neonatorum; Child; Child, Preschool; Develop | 2002 |
Post-resuscitation management of asphyxiated neonates.
Topics: Anticonvulsants; Asphyxia Neonatorum; Calcium; Cardiotonic Agents; Dobutamine; Drug Therapy, Combina | 2008 |
Monitoring of cerebral function after severe asphyxia in infancy.
Topics: Asphyxia; Asphyxia Neonatorum; Brain; Brain Damage, Chronic; Electroencephalography; Electrophysiolo | 1983 |
Cerebral blood flow velocities in postasphyxial term neonates.
Topics: Asphyxia Neonatorum; Blood Flow Velocity; Cerebrovascular Circulation; Dexamethasone; Glycerol; Huma | 1983 |
The influence of asphyxia on phenobarbital dosing requirements in neonates.
Topics: Aging; Asphyxia Neonatorum; Drug Administration Schedule; Female; Humans; Infant, Newborn; Kinetics; | 1984 |
Brain-orientated intensive care treatment in severe neonatal asphyxia. Effects of phenobarbitone protection.
Topics: Asphyxia Neonatorum; Blood Transfusion; Brain Damage, Chronic; Brain Edema; Critical Care; Humans; I | 1982 |
Predictive value of early continuous amplitude integrated EEG recordings on outcome after severe birth asphyxia in full term infants.
Topics: Asphyxia Neonatorum; Brain Damage, Chronic; Electroencephalography; Follow-Up Studies; Humans; Infan | 1995 |
Adverse effects of early phenobarbital administration in term newborns with perinatal asphyxia.
Topics: Anticonvulsants; Asphyxia Neonatorum; Humans; Infant, Newborn; Perinatal Care; Phenobarbital; Retros | 1998 |
Outcome of neonatal stroke in full-term infants without significant birth asphyxia.
Topics: Anticonvulsants; Apgar Score; Asphyxia Neonatorum; Cerebrovascular Disorders; Female; Gestational Ag | 1998 |
Phenobarbital and perinatal asphyxia.
Topics: Adult; Asphyxia Neonatorum; Dose-Response Relationship, Drug; Female; Humans; Hypnotics and Sedative | 1998 |
Clinical predictors of outcome in hypoxic ischaemic encephalopathy in term neonates.
Topics: Anticonvulsants; Apgar Score; Asphyxia Neonatorum; Cerebral Palsy; Cerebrovascular Disorders; Female | 1998 |
[Value of the intravenous route for the use of phenobarbital in asphyxiated full term newborn infants].
Topics: Asphyxia Neonatorum; Female; Humans; Infant, Newborn; Injections, Intravenous; Male; Phenobarbital | 1979 |
Use of activated charcoal to reduce elevated serum phenobarbital concentration in a neonate.
Topics: Administration, Oral; Asphyxia Neonatorum; Charcoal; Half-Life; Humans; Infant, Newborn; Male; Pheno | 1991 |
Neonatal hypoxic-ischemic encephalopathy: current management practices.
Topics: Academic Medical Centers; Asphyxia Neonatorum; Brain Ischemia; Electroencephalography; Humans; Infan | 1988 |
Safety of a higher loading dose of phenobarbital in the term newborn.
Topics: Asphyxia Neonatorum; Humans; Infant, Newborn; Phenobarbital; Seizures | 1985 |